FSD Pharma, Inc. is a publicly traded holding company, since May 2018.
FSD Pharma was founded by Thomas Fairfull, Zeeshan Saeed and Anthony Durkacz. The first initial of the last names of each of the founders represent the letters FSD.
FSD BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, FSD201 ultra-micronized palmitoylethanolamide (PEA). Ultra-Micro PEA stabilizes mast cells and down-regulates the pro-inflammatory cytokines to effectuate an anti-inflammatory response; it is also known to target the CB2 receptors of the endocannabinoid system of the human body.
FSD Pharma is actively looking to add suitable candidates to its family of compounds and molecules, which are in various stages of FDA (Food & Drug Administration USA) or HC (Health Canada) approved clinical trials, focused in targeting the receptors of the endocannabinoid system and or in the field of legal therapeutic psychedelics. FSD intends to do this by acquiring or investing in other companies which are in these fields and are in line with FSD’s strategic vision.